Actively Recruiting
Topotecan and Melphalan for Retinoblastoma
Led by Sun Yat-sen University · Updated on 2021-03-16
50
Participants Needed
1
Research Sites
355 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate topotecan and melphalan for retinoblastoma patients.
CONDITIONS
Official Title
Topotecan and Melphalan for Retinoblastoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with retinoblastoma
- Receiving eyeball-sparing treatment
You will not qualify if you...
- Disease progression during follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen University
Guangzhou, Guangdong, China, 510000
Actively Recruiting
Research Team
H
Huasheng Yang
CONTACT
H
Huijing Ye
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here